First-in-human administration of [ 161 Tb]Tb-SibuDAB and comparative dosimetry with standard [ 177 Lu]Lu-PSMA-I&T as part of the PROGNOSTICS phase Ia study.

MLA

Chirindel, Alin, et al. “First-in-Human Administration of [ 161 Tb]Tb-SibuDAB and Comparative Dosimetry with Standard [ 177 Lu]Lu-PSMA-I&T as Part of the PROGNOSTICS Phase Ia Study.” European Journal of Nuclear Medicine and Molecular Imaging, Dec. 2024. EBSCOhost, https://doi.org/10.1007/s00259-024-07009-w.

APA

Chirindel, A., Nicolas, G. P., Westerbergh, F., McDougall, L., Schmid, D. E., Geistlich, S., Tschan, V. J., Busslinger, S. D., Fokkema, A., Aceto, N., Bernhardt, P., van der Meulen, N. P., Müller, C., Wild, D., & Schibli, R. (2024). First-in-human administration of [ 161 Tb]Tb-SibuDAB and comparative dosimetry with standard [ 177 Lu]Lu-PSMA-I&T as part of the PROGNOSTICS phase Ia study. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-024-07009-w

Chicago

Chirindel, Alin, Guillaume P Nicolas, Frida Westerbergh, Lisa McDougall, David E Schmid, Susanne Geistlich, Viviane J Tschan, et al. 2024. “First-in-Human Administration of [ 161 Tb]Tb-SibuDAB and Comparative Dosimetry with Standard [ 177 Lu]Lu-PSMA-I&T as Part of the PROGNOSTICS Phase Ia Study.” European Journal of Nuclear Medicine and Molecular Imaging, December. doi:10.1007/s00259-024-07009-w.